Australian medical technology company Ferronova has reported preliminary findings from the MAGMAP multicentre trial evaluating its nanoparticle-based lymph node mapping technology in patients with gastric and oesophageal cancer.
The 62-patient study is assessing the safety and feasibility of the platform for identifying lymph nodes that drain a primary tumour, commonly referred to as sentinel lymph nodes.
The findings were presented at the 22nd ISDE World Congress for Esophageal Diseases in Kyoto, Japan.